Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi's fourth-quarter operating income declined 5% as a weaker U.S. dollar and cheaper rivals competing against its established multiple sclerosis drug outweighed growing sales of anti-inflammatory drug Dupixent.

Sanofi Q4 earnings burdened by weak dollar, generic competition

François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee Paris, February 1, 2024. François-Xavier Roger will be appointed Chief Financial Officer and a member of Sanofi's Executive Committee effective April 1, 2024.

Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee

Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline

Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline

Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Sanofi (SNY) Might Surprise This Earnings Season

MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced a worldwide collaboration with Sanofi (EURONEXT: SAN and NASDAQ: SNY) to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases. The collaboration will focus on advancing Synthekine's multiple approaches to optimizing IL-10, with the goal of developing selective agonists that expand therapeutic index. “We look forward to working with Synthekine.

Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases

Regeneron Pharmaceuticals

The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to treat an allergic inflammation of the esophagus in children aged one to 11 years old and weighing at least 15 kg, the companies said on Thursday.

US FDA approves Dupixent to treat younger kids with esophageal condition

Dupixent ® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo   Expanded indication marks second disease for which Dupixent is approved in children this young, underscoring the commitment to bringing therapies to young patients with significant unmet needs   EoE is one of five FDA-approved indications for Dupixent in the U.S. for which type 2 inflammation is an underlying driver Paris and Tarrytown, N.Y. January 25, 2024.

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)

Inhibrx Biosciences Inc

Inhibrx (INBX) shares jumped over 7% in early trading Tuesday after Sanofi (SNY) said it would buy Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs to treat rare diseases.

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

Sanofi is getting into a liver disease treatment space with its $1.7 billion acquisition of biotech stock Inhibrx. But Sanofi stock toppled.

Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx

Sanofi plans to buy assets from U.S. biopharmaceutical company Inhibrx in a deal valued at up to $2.2 billion.

Sanofi to Buy Rare-Disease Assets From Inhibrx

French healthcare company Sanofi has agreed to buy the drug development project INBRX-101 from its parent company Inhibrx Inc for around $2.2 billion, the companies said on Tuesday.

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Acquisition supports Sanofi's portfolio growth strategy and complements 30-year heritage in rare diseases and proven industry leadership in immunology and inflammation   For each Inhibrx share, Inhibrx shareholders will receive $30.0 in cash, a contingent value right (CVR) of $5.0 and 0.25 shares of a new publicly traded company that will retain Inhibrx's non-INBRX-101 assets (“New Inhibrx”)  Paris, January 23, 2024. Sanofi and Inhibrx, Inc. (“Inhibrx”), a publicly traded clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, have entered into a definitive agreement under which Sanofi has agreed to acquire Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx.

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets of Inhibrx, Inc. Sanofi to pay off Inhibrx's outstanding debt balance and capitalize New Inhibrx with $200 million in cash SAN DIEGO , Jan. 23, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") and Sanofi (Nasdaq: SNY) ("Sanofi") today announced that the companies have entered into a definitive agreement under which Aventis Inc., a Pennsylvania corporation (a subsidiary of Sanofi) will acquire all the assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD"). Immediately prior to the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline and its corporate infrastructure, will be spun out from the Company into a new publicly traded company, Inhibrx Biosciences, Inc. ("New Inhibrx").

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

Sanofi SA (EPA: SAN) has “perhaps the world's best immunology pipeline”, says Paul Hudson – chief executive of the healthcare giant.

Sanofi has the ‘world's best immunology pipeline': CEO Paul Hudson

Novo Nordisk

GlaxoSmithKline

Drug stocks GSK, Sanofi, Merck KGaA, and Novartis look set for a good year on strong cash flows and attractive valuations, says UBS.

4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn't One.

Merck

Teva Pharmaceutical

There's a revolution in immunology that could completely shift a paradigm biotech stocks. And Big Pharma is paying billions to get in.

Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space

Sanofi is hoping that by sponsoring the Olympic Games it can attract new talent, reward existing staff and shake off the French drugmaker's conservative image.

Drugs group Sanofi makes Olympic jump in rebrand bid

Sanofi (SNY) Presents at J.P. Morgan 42nd Annual Healthcare Conference Call Transcript

Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee Paris, January 9, 2024. Brian Foard, a healthcare industry veteran and Sanofi leader in the U.S., has been named Head of the company's Specialty Care Global Business Unit (GBU).

Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee

Amgen

Bristol-Myers

Gilead Sciences

Novartis

Pfizer

The Pharmaceutical segment offers human health pharmaceutical products in: Oncology, Hospital acute care Immunology Neuroscience Virology Cardiovascular and diabetes Vaccine products, such as preventive pediatric, adolescent, and adult vaccines The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.

7 Rock-Solid Healthcare Dividend Stocks to Buy in January

ALAMEDA, Calif.--(BUSINESS WIRE)-- #CRISPR--Collaboration to advance in vivo genetic medicines using Scribe's CRISPR by Design™ approach broadens with Sanofi's selection of a second target.

Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target

AstraZeneca

AstraZeneca and Sanofi's respiratory syncytial virus (RSV) immunization for infants has been approved in China, the London-listed drugmaker said on Tuesday.

AstraZeneca, Sanofi's RSV infant shots approved in China

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Sanofi (SNY) is a Strong Value Stock

Sanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint.

Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program

French pharmaceuticals giant Sanofi SAN, -0.43% on Thursday said it would be halting development of a promising cancer treatment after the cutting-edge candidate failed to show better outcomes than a widely-used chemotherapy drug in final stage trials.

News for Sanofi Stock (SNY)